Trovagene, Inc. (NASDAQ: TROV), announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. On Friday shares of TrovaGene, Inc. (NASDAQ:TROV) closed at $4.47.
Actinium Pharmaceuticals Inc. (NYSE MKT:ATNM) announced the pricing of an underwritten public offering of an aggregate 4444444 shares of its common stock and warrants to purchase an aggregate of 3333333 shares of the Company’s common stock at a combined price to the public of $4.50. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) in last trading activity decreased -24.45% to close at $3.77. Company weekly performance is -30.06% while its quarterly performance stands at -49.40%. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) is -74.87% away from its 52 week high.
Ohr Pharmaceutical Inc. (NASDAQ:OHRP) is raising $25 million to fund dual pivotal phase III studies of its Lucentis-boosting eye drops, OHR-102 (squalamine), in newly diagnosed patients with wet age-related macular degeneration (AMD). If all goes well, the company could file a new drug application (NDA) by about mid-2017. On last trading day Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) decreased -8.38% to close at $7.00. Its volatility for the week is 9.89% while volatility for the month is 6.69%. OHRP’s EPS growth for past 5 years was -32.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) monthly performance is -16.67%.
On 28 January, Advaxis, Inc. (NASDAQ:ADXS), announced an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology. Advaxis, Inc. (NASDAQ:ADXS) has 4.00% insider ownership while its institutional ownership stands at 31.60%. In last trading activity company’s stock closed at $7.53.
On 3 February, Kite Pharma, Inc., (NASDAQ:KITE), announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. On last trading day Kite Pharma, Inc. (NASDAQ:KITE) decreased -5.28% to close at $60.27. Its volatility for the week is 7.62% while volatility for the month is 10.46%. Kite Pharma, Inc. (NASDAQ:KITE) monthly performance is -15.08%.